Valerie Borel

Valerie Borel

Auto-generated profile, based on publicly available information

Valerie Borel


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2025 in bioRxiv
Verified
Preprint
Open access
SSSandra Segura-Bayona
Sandra Segura-Bayona
VBValerie Borel
Valerie Borel
TSTyler H Stanage
Tyler H Stanage
MMMarija Maric
Marija Maric
MWMelanie Walter
Melanie Walter
SBSimon J Boulton
Simon J Boulton
The tRNA nuclease SLFN11 is epigenetically silenced in ∼50% of treatment-naive tumours and is the strongest predictor of chemoresistance but why it is frequently inactivated in cancer is unknown. To acquire immortality, cancer cells can activate alternative lengthening of telomeres (ALT), typically accompanied by ATRX loss. Here, we implicate SLFN11 in sensing telomere replication stress, triggering eradication of ATRX deficient cells prior to ALT establishment. Whereas progressive telomere shortening of cells lacking telomerase and ATRX leads to telomere crisis and cell death, SLFN11 loss confers tolerance to PML-BLM dependent ALT intermediates, permitting emergence of ALT survivors. We propose that during tumorigenesis SLFN11 inactivation is selected as means to tolerate endogenous replication stress following telomere crisis, leading to the development of therapy resistant tumours before treatment.